ASBPNasdaq

Aspire Biopharma Holdings Inc.

Healthcare·Cardiovascular·Commercial·Estero, FL, United States
Cardiovascular

Aspire Biopharma Holdings Inc. (ASBP): 4 pipeline candidates · ~6 mo cash runway. Updated within the last hour.

6.9/10

BioSniper Score

4-factor signal · derived from public data

Cash Runway1.7

6.2 months

Financial Health8.7

D/E 0.84 · 0% dilution

Pipeline Maturity10.0

Lead: Approved

Pipeline Breadth7.2

4 candidates

Catalyst MomentumN/A

N/A

Insider SignalN/A

N/A

A transparent, data-derived signal for Aspire Biopharma Holdings Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.

Key Financials

Market Cap

$7.8M

Cash

$5.9M

Quarterly Burn

$3.0M

Runway

6.2 mo

Revenue

$28K

Cash Runway vs Catalysts

Tracked catalysts land within the current projected cash runway.

Cash ends ~Dec 2026
Today~7 mo out
Catalyst within runway

Pipeline (4 candidates)

Institutional Holdings

Source: SEC Form 13F · as of Mar 2026

Institutional holders

10

Total value held

$150K

HolderSharesValue
morgan stanley76,955$79K
geode capital management, llc43,384$45K
vanguard capital management llc15,718$16K
toronto dominion bank5,000$5K
vanguard fiduciary trust co2,856$3K
citigroup inc1,846$2K
osaic holdings, inc.2$2
avion wealth1,352$1
caitong international asset management co., ltd1$1
sbi securities co., ltd.1$1
·CEO: Mr. Kraig T. Higginson

Frequently asked questions

How many drug candidates are in Aspire Biopharma Holdings Inc.'s pipeline?

Aspire Biopharma Holdings Inc. (ASBP) has 4 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.

What is Aspire Biopharma Holdings Inc.'s lead drug candidate?

Aspire Biopharma Holdings Inc.'s most advanced tracked candidate is aspireassist (Approved) for Gastroenterology, Urology.

What is Aspire Biopharma Holdings Inc.'s cash runway?

Based on its most recent reported cash balance and quarterly burn rate, Aspire Biopharma Holdings Inc. has approximately 6.2 months of cash runway.

What is Aspire Biopharma Holdings Inc.'s market capitalization?

Aspire Biopharma Holdings Inc.'s market capitalization is approximately $7.8M.

Who is the CEO of Aspire Biopharma Holdings Inc.?

Mr. Kraig T. Higginson is the chief executive officer of Aspire Biopharma Holdings Inc. (ASBP).

Get the full picture on Aspire Biopharma Holdings Inc.

Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.